A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders

References

• Adler DA, McLaughlin TJ, Rogers WH, Chang H, Lapitsky L, Lerner D. 2006. Job performance deficits due to depression. Am J Psychiatry 163:1569–1576.
   PubMed Web of Science ®Google Scholar
• Andronis L, Barton P, Bryan S. 2009. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technol Assess 13:iii, ix–xi, 1–61.
   Google Scholar
• APA. 2000. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157:1–45.
   Web of Science ®Google Scholar
• Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. 2003. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 23:563–567.
   PubMed Web of Science ®Google Scholar
• Arranz M, Kapur S. 2008. Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 34: 1130–1144.
   PubMed Web of Science ®Google Scholar
• Aydemir O, Ergun H, Soygur H, Kesebir S, Tulunay C. 2009. [Quality of life in major depressive disorder: a cross-sectional study]. Turk Psikiyatri Derg 20:205–212.
   PubMed Web of Science ®Google Scholar
• Azimi NA, Welch HG. 1998. The effectiveness of cost-effectiveness analysis in containing costs. J Gen Intern Med 13: 664–669.
   PubMed Web of Science ®Google Scholar
• Banks S, Pandiani G, Gauvin L, Reardon M, Schacht L, Zovistowski A. 1998. Practice patterns and hospitalization rates. Admin Policy Ment Health 26:33–44.
   PubMed Web of Science ®Google Scholar
• Bauer M, Monz BU, Montejo AL, Quail D, Dantchev N, Demyttenaere K, . 2008. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry 23:66–73.
   PubMed Web of Science ®Google Scholar
• Bellivier F, Chaste P, Malafosse A. 2004. Association between the TPH gene A218C polymorphism and suicidal behavior: a meta–analysis. Am J Med Genet B Neuropsychiatr Genet 124B:87–91.
   PubMed Web of Science ®Google Scholar
• Bender A, Farvolden P. 2008. Depression and the workplace: a progress report. Curr Psychiatry Rep 10:73–79.
   PubMedGoogle Scholar
• Birnbaum HG, Ben-Hamadi R, Greenberg PE, Hsieh M, Tang J, Reygrobellet C. 2009. Determinants of direct cost differences among US employees with major depressive disorders using antidepressants. Pharmacoeconomics 27:507–517.
   PubMed Web of Science ®Google Scholar
• Bradvik L, Mattisson C, Bogren M, Nettelbladt P. 2008. Long-term suicide risk of depression in the Lundby cohort 1947–1997 – severity and gender. Acta Psychiatr Scand 117:185–191.
   PubMed Web of Science ®Google Scholar
• Buist-Bouwman MA, De Graaf R, Vollebergh WA, Alonso J, Bruffaerts R, Ormel J. 2006. Functional disability of mental disorders and comparison with physical disorders: a study among the general population of six European countries. Acta Psychiatr Scand 113:492–500.
   PubMed Web of Science ®Google Scholar
• Cascade E, Kalali A, Kennedy S. 2009. Real-world data on SSRI antidepressant side effects. Psychiatry 6:16–18.
   PubMedGoogle Scholar
• Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, . 2003. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386–389.
   PubMed Web of Science ®Google Scholar
• Cheng IC, Liao SC, Lee MB, Tseng MM. 2007. Predictors of treatment response and length of stay for inpatients with major depression. J Formos Med Assoc 106:903–910.
   PubMed Web of Science ®Google Scholar
• Comings DE, Gade-Andavolu R, Gonzalez N, Wu S, Muhleman D, Blake H, . 2000. A multivariate analysis of 59 candidate genes in personality traits: the temperament and character inventory. Clin Genet 58:375–385.
   PubMed Web of Science ®Google Scholar
• Cuffel BJ, Azocar F, Tomlin M, Greenfield SF, Busch AB, Croghan TW. 2003. Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. J Clin Psychiatry 64:397–402.
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W, . 2001. Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry 62(Suppl 22):30–33.
   PubMed Web of Science ®Google Scholar
• Drago A, De Ronchi D, Serretti A. 2009. Pharmacogenetics of antidepressant response: an update. Hum Genomics 3:257–274.
   PubMedGoogle Scholar
• Ehli EA, Hu Y, Lengyel-Nelson T, Hudziak JJ, Davies GE. 2011. Identification and functional characterization of three novel alleles for the serotonin transporter-linked polymorphic region. Mol Psychiatry (doi:10.1038/mp.2010.130).
   PubMed Web of Science ®Google Scholar
• Eker SS, Kirli S, Akkaya C, Cangur S, Sarandol A. 2009. Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women? World J Biol Psychiatry 10(4pt2):400–408.
   PubMed Web of Science ®Google Scholar
• Fenwick E, Biford S. 2005. A guide to cost-effectiveness acceptability curve. Br J Psychiatry 187:106–108.
   PubMed Web of Science ®Google Scholar
• Ferrier IN. 1999. Treatment of major depression: is improvement enough? J Clin Psychiatry 60(Suppl 6):10–14.
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh-Geiss A, Krebs EE, . 2008. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 31:851–865.
   PubMed Web of Science ®Google Scholar
• Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. 2008. The STAR*D study: treating depression in the real world. Cleve Clin J Med 75:57–66.
   PubMed Web of Science ®Google Scholar
• Golenko-Ginzburg D. 1988. On the distribution of activity time in PERT. J Op Res Soc 39:767–771.
   Web of Science ®Google Scholar
• Grassi L, Rossi A, Barraco A. 2009. Factors Influencing Depression Endpoints Research (FINDER): baseline results of Italian patients with depression. Ann Gen Psychiatry 8:14.
   PubMedGoogle Scholar
• Hamilton M. 1967. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296.
   PubMed Web of Science ®Google Scholar
• Hewett K, Gee M, Krishen A, Wunderlich H, Le Clus A, Evoniuk G, . 2010. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 24:1209–1216.
   PubMed Web of Science ®Google Scholar
• Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, . 2006. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78:815–826.
   PubMed Web of Science ®Google Scholar
• Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, . 2007. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 64:783–792.
   PubMed Web of Science ®Google Scholar
• Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A, . 2009. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 195:30–8.
   PubMed Web of Science ®Google Scholar
• Hughes S, Cohen D. 2009. A systematic review of long-term studies of drug treated and non-drug treated depression. J Affect Disord 118:9–18.
   PubMed Web of Science ®Google Scholar
• Jewell N. 2004. Statistics for epidemiology. Boca Raton, FL: Chapman and Hall/CRC.
   Google Scholar
• Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, . 1998. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50:97–108.
   PubMed Web of Science ®Google Scholar
• Kasper S, Montgomery SA, Moller HJ, vanOers HJ, Shutte AJ, Vrijland P, . 2007. Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. World J Biol Psychiatry 29:1–9.
   Google Scholar
• Kato M, Serretti A. 2010. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15:473–500.
   PubMed Web of Science ®Google Scholar
• Kato M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K, Fukuda T, . 2005. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 20:151–156.
   PubMed Web of Science ®Google Scholar
• Kato M, Zanardi R, Rossini D, De Ronchi D, Okugawa G, Kinoshita T, . 2009. 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. Psychiatry Res 167:97–105.
   PubMed Web of Science ®Google Scholar
• Keers R, Uher R, Huezo-Diaz P, Smith R, Jaffee S, Rietschel M, . 2011. Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenom J 11:138 145.
   Google Scholar
• Kendler KS. 2005. “A gene for...”: the nature of gene action in psychiatric disorders. Am J Psychiatry 162:1243–1252.
   PubMed Web of Science ®Google Scholar
• Khan A, Kolts RL, Brodhead AE, Krishnan KR, Brown WA. 2006. Suicide risk analysis among patients assigned to psychotropics and placebo. Psychopharmacol Bull 39:6–14.
   PubMedGoogle Scholar
• Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, . 2006. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. J Am Med Assoc 296:1609–1618.
   PubMed Web of Science ®Google Scholar
• Kirsch I, Deacon B, Huedo-Medina T, Scoboria A, Moore T, Johnson B. 2008. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:e45.
   PubMed Web of Science ®Google Scholar
• Koponen H, Jokelainen J, Keinanen-Kiukanniemi S, Vanhala M. 2010. Depressive symptoms and 10-year risk for cardiovascular morbidity and mortality. World J Biol Psychiatry 11(6): 834–839.
   PubMed Web of Science ®Google Scholar
• Laje G, Perlis RH, Rush AJ, McMahon FJ. 2009. Pharmacogenetics studies in STAR*D: strengths, limitations, and results. Psychiatr Serv 60:1446–1457.
   PubMed Web of Science ®Google Scholar
• Lazary J, Lazary A, Gonda X, Benko A, Molnar E, Juhasz G, . 2008. New evidence for the association of the serotonin transporter gene (SLC6A4) haplotypes, threatening life events, and depressive phenotype. Biol Psychiatry 64:498–504.
   PubMed Web of Science ®Google Scholar
• Lepine JP. 2001. Epidemiology, burden, and disability in depression and anxiety. J Clin Psychiatry 62(Suppl 13):4–10; discussion 11–12.
   PubMed Web of Science ®Google Scholar
• Llorca PM, Fernandez JL. 2007. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract 61:702–710.
   PubMed Web of Science ®Google Scholar
• McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, . 2006. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78:804–814.
   PubMed Web of Science ®Google Scholar
• Melartin TK, Rytsala HJ, Leskela US, Lestela-Mielonen PS, Sokero TP, Isometsa ET. 2005. Continuity is the main challenge in treating major depressive disorder in psychiatric care. J Clin Psychiatry 66:220–227.
   PubMed Web of Science ®Google Scholar
• Min W, Li T, Ma X, Li Z, Yu T, Gao D, . 2009. Monoamine transporter gene polymorphisms affect susceptibility to depression and predict antidepressant response. Psychopharmacology 205:409–417.
   PubMed Web of Science ®Google Scholar
• Moller HJ 2003. Suicide, suicidality and suicide prevention in affective disorders. Acta Psychiatr Scand Suppl 73–80.
   PubMed Web of Science ®Google Scholar
• Mrazek DA, Rush AJ, Biernacka JM, O'Kane DJ, Cunningham JM, Wieben ED, . 2009. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 150B: 341–351.
   PubMed Web of Science ®Google Scholar
• Munafo MR, Durrant C, Lewis G, Flint J. 2009. Gene X environment interactions at the serotonin transporter locus. Biol Psychiatry 65:211–219.
   PubMed Web of Science ®Google Scholar
• Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. 2004. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 61:1163–1169.
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health. 2005. Depression: Management of depression in primary and secondary care. National Clinical Practice Guideline. London: British Psychological Society & Gaskell.
   Google Scholar
• Nieuwstraten C, Dolovich L. 2001. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother 35:1608–1613.
   PubMed Web of Science ®Google Scholar
• OECD. 2009. OECD Health Data 2009 (ww.ecosante.org).
   Google Scholar
• Papakostas GI, Montgomery SA, Thase ME, Katz JR, Krishen A, Tucker VL. 2007. Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials. J Clin Psychiatry 68:1907–1912.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Trivedi MH, Alpert JE, Seifert CA, Krishen A, Goodale EP, . 2008. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res 42:134–140.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Charles D, Fava M. 2010. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry 11(2pt2):300–307.
   PubMed Web of Science ®Google Scholar
• Perlis RH, Patrick A, Smoller JW, Wang PS. 2009. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology 34:2227–2236.
   PubMed Web of Science ®Google Scholar
• Pezawas L, Meyer-Lindenberg A, Goldman AL, Verchinski BA, Chen G, Kolachana BS, . 2008. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry 13:709–716.
   PubMed Web of Science ®Google Scholar
• Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, . 2000. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23:587–590.
   PubMed Web of Science ®Google Scholar
• Poluzzi E, Motola D, Silvani C, De Ponti F, Vaccheri A, Montanaro N. 2004. Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement. Eur J Clin Pharmacol 59:825–831.
   PubMed Web of Science ®Google Scholar
• Popp J, Leucht S, Heres S, Steimer W. 2006. Serotonin transporter polymorphisms and side effects in antidepressant therapy – a pilot study. Pharmacogenomics 7:159–166.
   PubMed Web of Science ®Google Scholar
• Posternak MA, Zimmerman M. 2003. How accurate are patients in reporting their antidepressant treatment history? J Affect Disord 75:115–124.
   PubMed Web of Science ®Google Scholar
• Rausch JL, Johnson ME, Fei Y-J, Li JQ, Shendarkar N, Mac Hobby H, . 2002. Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome. Biol Psychiatry 51:723–732.
   PubMed Web of Science ®Google Scholar
• Reimherr F, Amsterdam J, Dunner D, Adler L, Zhang S, Williams D, . 2010. Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine. Psychiatry Res 175:67–73.
   PubMed Web of Science ®Google Scholar
• Revicki D, Wood M. 1998. Patient-assigned health state utilities for depression related outcomes: differences by depression severity and antidepressant medications. J Affect Disord 48: 25–36.
   PubMed Web of Science ®Google Scholar
• Rocca P, Mingrone C, Mongini T, Montemagni C, Pulvirenti L, Rocca G, . 2010. Outcome and length of stay in psychiatric hospitalization, the experience of the University Clinic of Turin. Soc Psychiatry Psychiatr Epidemiol 45: 603–610.
   PubMed Web of Science ®Google Scholar
• Rush A, Trivedi M, Wisniewski S, Nierenberg A, Stewart J, Warden D, . 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917.
   PubMed Web of Science ®Google Scholar
• Rytsala HJ, Melartin TK, Leskela US, Sokero TP, Lestela- Mielonen PS, Isometsa ET. 2005. Functional and work disability in major depressive disorder. J Nerv Ment Dis 193: 189–195.
   PubMed Web of Science ®Google Scholar
• Sapin C, Fantino B, Nowicki ML, Kind P. 2004. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes 2: 20.
   PubMedGoogle Scholar
• Sarnes MW, Frankum LE. 2004. Pharmacoeconomic evaluation of antidepressant therapies. Manag Care 13:34–41.
   PubMedGoogle Scholar
• Sawada N, Uchida H, Suzuki T, Watanabe K, Kikuchi T, Handa T, . 2009. Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry 9:38.
   PubMed Web of Science ®Google Scholar
• Serna M, Cruz I, Real J, Gascó E, Galván L. 2010. Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database. Eur Psychiatry 25:206–213.
   PubMed Web of Science ®Google Scholar
• Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D, Zanardi R. 2004. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet 129B:36–40.
   PubMed Web of Science ®Google Scholar
• Serretti A, Artioli P, Quartesan R, 2005. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genom 15:61–67.
   PubMed Web of Science ®Google Scholar
• Serretti A, Kato M, De Ronchi D, Kinoshita T. 2007a. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 12:247–257.
   PubMed Web of Science ®Google Scholar
• Serretti A, Kato M, Kennedy J. 2007b. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenom J 8:90–100.
   PubMed Web of Science ®Google Scholar
• Shaw J, Zachr W. 2002. Application of probabilistic sensitivity analysis in decision analytic modeling. Pract Pharmacoeconom 37:32–40.
   Google Scholar
• Sheehan DV, Keene MS, Eaddy M, Krulewicz S, Kraus JE, Carpenter DJ. 2008. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs 22:963–973.
   PubMed Web of Science ®Google Scholar
• Smeraldi E, Zanardi R, Benedetti F, Dibella D, Perez J, Catalano M. 1998. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3(6):508–511.
   PubMed Web of Science ®Google Scholar
• Smits KM, Smits LJ, Schouten JS, Peeters FP, Prins MH. 2007. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model. Clin Ther 29:691–702.
   PubMed Web of Science ®Google Scholar
• Smits KM, Smits LJ, Peeters FP, Schouten JS, Janssen RG, Smeets HJ, . 2008. The influence of 5-HTTLPR and STin2 polymorphisms in the serotonin transporter gene on treatment effect of selective serotonin reuptake inhibitors in depressive patients. Psychiatr Genet 18:184–190.
   PubMed Web of Science ®Google Scholar
• Soeteman DI, Timman R, Trijsburg RW, Verheul R, Busschbach JJ. 2005. Assessment of the burden of disease among inpatients in specialized units that provide psychotherapy. Psychiatr Serv 56:1153–1155.
   PubMed Web of Science ®Google Scholar
• Stahl S, Muntner M. 1998. Essential psychopharmacology. Neuroscientific basis and practical applications. Cambridge: Cambridge University Press.
   Google Scholar
• Stein MB, Cantrell CR, Sokol MC, Eaddy MT, Shah MB. 2006. Antidepressant adherence and medical resource use among managed care patients with anxiety disorders. Psychiatr Serv 57:673–680.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Valuck R, Saseen J, MacFall HM. 2004. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 18:911–932.
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Sen S, Bhagwagar Z. 2010. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry 68:536–543.
   PubMed Web of Science ®Google Scholar
• Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, . 2005. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 66:974–981.
   PubMed Web of Science ®Google Scholar
• Tournier M, Moride Y, Crott R, du Fort GG, Ducruet T. 2009. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population. J Affect Disord 115:160–166.
   PubMed Web of Science ®Google Scholar
• Turecki G, Zhu Z, Tzenova J, Lesage A, Seguin M, Tousignant M, . 2001. TPH and suicidal behavior: a study in suicide completers. Mol Psychiatry 6:98–102.
   PubMed Web of Science ®Google Scholar
• Villafuerte SM, Vallabhaneni K, Sliwerska E, McMahon FJ, Young EA, Burmeister M. 2009. SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet 19:281–291.
   PubMed Web of Science ®Google Scholar
• Walsh BT, Seidman SN, Sysko R, Gould M. 2002. Placebo response in studies of major depression: variable, substantial, and growing. J Am Med Assoc 287:1840–1847.
   PubMed Web of Science ®Google Scholar
• Warden D, Trivedi MH, Wisniewski SR, Davis L, Nierenberg AA, Gaynes BN, . 2007. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry 164:1189–1197.
   PubMed Web of Science ®Google Scholar
• Watkins KE, Burnam MA, Orlando M, Escarce JJ, Huskamp HA, Goldman HH. 2009. The health value and cost of care for major depression. Value Health 12:65–72.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. 1996. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. J Am Med Assoc 276:1253–1258.
   PubMed Web of Science ®Google Scholar
• Zetin M, Hoepner CT, Bjornson L. 2006. Rational antidepressant selection: applying evidence-based medicine to complex real-world patients. Psychopharmacol Bull 39:38–104.
   PubMedGoogle Scholar